Basic Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Pediatr. Jan 9, 2022; 11(1): 48-60
Published online Jan 9, 2022. doi: 10.5409/wjcp.v11.i1.48
Impact of stimulant medication on behaviour and executive functions in children with attention-deficit/hyperactivity disorder
Tasmia Hai, Hanna A Duffy, Julie Anne Lemay, Jean François Lemay
Tasmia Hai, Hanna A Duffy, Werklund School of Education, University of Calgary, Calgary, AB T2N 1N4, Canada
Julie Anne Lemay, Jean François Lemay, Department of Paediatrics, Alberta Children's Hospital/Cumming School of Medicine, University of Calgary, Calgary, AB T3B 6A8, Canada
Author contributions: Hai T assisted with data collection, analyzed and interpreted the data and wrote the manuscript; Duffy HA assisted with data collection and reviewing of the manuscript; Lemay JA assisted with data collection; Lemay JF is the principal investigator of the study, designed the study and edited the manuscript; all authors approved the final version of the article.
Supported by the Alberta Children's Hospital Foundation, Werklund School of Education, University of Calgary.
Institutional review board statement: Ethics approval for the following research has been renewed by the Conjoint Health Research Ethics Board (CHREB) at the University of Calgary. The CHREB is constituted and operates in compliance with the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2); Health Canada Food and Drug Regulations Division 5; Part C; ICH Guidance E6: Good Clinical Practice and the provisions and regulations of the Health Information Act, RSA 2000 c H-5. Ethics ID: REB15-3068_REN4.
Conflict-of-interest statement: The authors declare no competing financial interests. No conflict of interest to report.
Data sharing statement: Dataset available from the corresponding author at jf.lemay@ahs.ca.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jean François Lemay, MD, FRCPC, Professor, Department of Paediatrics, Alberta Children's Hospital/Cumming School of Medicine, University of Calgary, 28 Oki Drive, NW, Room C4-627, Calgary, AB T3B 6A8, Canada. jf.lemay@ahs.ca
Received: March 24, 2021
Peer-review started: March 24, 2021
First decision: June 17, 2021
Revised: July 8, 2021
Accepted: December 2, 2021
Article in press: December 2, 2021
Published online: January 9, 2022
Processing time: 289 Days and 5.2 Hours
Core Tip

Core Tip: Parents of children with attention-deficit/hyperactivity disorder reported improvements in executive function and behaviours during the methylphenidate trial, but these improvements did not sustain at the long-term follow up condition. Combining screening tools and neuropsychological assessments may be useful for monitoring psychostimulant medication responses as children enter their adolescent years.